retatrutide drops More data on dropped today at the ADA conference!! Reta is an investigational -not FDA approved yet- once-weekly medication that simultaneously activates the GIP, GLP-1, and glucagon receptors In the Phase Retatrutide Significantly Reduces Visceral Fat

Diet control, moderate exercise, behavior modification programs, bariatric surgery and prescription drug treatment are the major interventions used to help people lose weight

doi: 10.1016/j.atherosclerosis.2019.11.021

In France, public reimbursement is beginning to regularise access for the most severely affected patients

Cardiomyocyte/cardiac fibroblast dysfunction is related to abnormal proliferation, apoptosis, hypertrophy, as well as inflammation and fibrosis, which may be caused by mitochondrial dysfunction and metabolic disorders

Both are given as a once-weekly injection that you learn to do yourself at home